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Abstract We report an unusual case of endometrial ade-
nocarcinoma in a 80-year-old woman who underwent mas-
tectomy for breast cancer at 68 years of age. The tumor
diVusely involved the entire thickness of the myometrium.
Atypical cells throughout the tumor contained abundant
oxiphilic cytoplasm and were arranged in a solid or solid-
tubular nests in a focal papillary manner. Components of
the carcinoma were focally observed in situ. The tumor was
classiWed according to the International Federation of
Gynecology and Obstetrics (FIGO) as grade 2 and stage
IIIa. Immunohistochemistry revealed that the tumor cells
were positive for p53 but negative for vimentin, estrogen,
and progesterone receptors, GCDFP-15, and mammaglo-
bin. They were positive for antimitochondrial antigen and
thyroid transcription factor-1. The Ki-67 labeling index was
approximately 50%. Immunostaining revealed endometrial
oncocytic carcinoma. Distinguishing between primary uter-
ine neoplasm and carcinoma caused by metastasis of breast
cancer appears important.
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Introduction
Pure oncocytic carcinoma of the endometrium is very rare,
and few such cases have been reported [1]. Tumor cells
possess oncocytic cytoplasm, which contains many mito-
chondria, as observed in ultrastructural studies [1]. Immu-
nohistochemistry reveals that these tumors are positive for
p53 and negative for estrogen receptor (ER) and progester-
one receptor (PgR) [1]. The immunostaining pattern in pure
oncocytic carcinoma is diVerent from that in common
endometrioid adenocarcinoma [2]. Thyroid transcription
factor 1 (TTF-1) expression in some endometrial cancers
has been recently reported [3]. The breast cancer of this
patient was resected 12 years ago. Breast cancers occasion-
ally metastasize to the endometrium [4]. The immunohisto-
chemical proWle diVers between breast cancers and
oncocytic endometrial carcinoma [1, 5]. Therefore, in this
case we could diVerentiate between endometrial oncocytic
carcinoma and endometrial carcinoma metastasized from
breast cancer.
Case report
A 80-year-old woman, gravida 2, para 2, was admitted to
the Tokai University Hospital with the chief complaint of
genital bleeding. She had a history of breast cancer for the
last 12 years, which was resected, following which she
underwent postoperative chemotherapy (tamoxifen) for
1 year. The cancer was not recurrent until this episode.
Endometrial cancer was suggested by ultrasonography and
computed tomography scans. No tumor lesions were
detected in other sites, such as the thyroid and adrenal
glands. There was no local recurrence of breast cancer. The
tumor markers CEA, CA19-9, and CA125 were within
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The FIGO stage of the tumor was clinically diagnosed as
stage Ib endometrial carcinoma, and the patient underwent
hysterectomy, bilateral salpingo-oophorectomy, and pelvic
lymph node dissection. Ascitic Xuid is not found clinically.
However, tumor cells are detected by peritoneal wash. The
FIGO stage was pathologically diagnosed as stage IIIa.
The patient was treated with chemotherapy (paclitaxel
and carboplatin). No recurrence of the tumor was found
5 months after surgery.
Materials and methods
Histological studies included light microscopic, histochem-
ical, and immunohistochemical examinations. Sections
were processed and stained simultaneously for each anti-
body by the indirect immunoperoxidase method using a
manual technique or an automatic immunostainer (Ventana,
Tucson, AZ). Envision/HRP kits (DAKO, Carpinteria, CA)
were used for detection using the manual technique. As
shown in Table 1, ten commercially available antibodies
were used in this study to analyze the tumors. These
included antimitochondrial antigen (AMA), p53, ER, PgR,
GCDFP-15, mammaglobin (MMG), c-erbB-2, TTF-1, thy-
roglobulin, and Ki-67 antibodies. The results of immuno-
staining for each antibody were evaluated. When fewer
than 50% cells were positively stained, the results were
classiWed as + and when more than 50% cells were stained
positively they were classiWed as ++.
Fig. 1 Endophytic and exophytic growth of a solid mass was found in
the uterine body
Fig. 2 Pathological Wndings of the endometrial oncocytic carcinoma.
a Low-power view showing areas of solid and papillary architecture.
Hematoxylin and eosin, original magniWcation £20. b The tumor cells
had Wne oxiphilic cytoplasm. Hematoxylin and eosin, original magni-
Wcation £100
Table 1 Primary antibodies 
used in immunohistochemistry Antibody Code or clone Manufacturer Dilution Antigen retrieval
AMA 113-1 Biogenex 1:50 Boiled using citrate buVer/pH 6.0
p53 DO-7 Ventana Autostainer
ER 6F11 Ventana Autostainer
PgR 16 Ventana Autostainer
GCDFP-15 D6 Covance 1:50 None
MMG 304-1A5 Dako 1:20 Boiled using citrate buVer/pH 6.0
c-erbB-2 PN2A Dako 1:50 Boiled using citrate buVer/pH 6.0
TTF-1 SPT-24 Novocastra 1:50 Boiled using citrate buVer/pH 6.0
TG A0251 Dako 1:100 None
Ki-67 PI MIB-1 Dako 1:50 Boiled using citrate buVer/pH 6.0123
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Macroscopically, the tumor was a whitish solid mass,
5 cm £ 6 cm £ 4 cm in size. The tumor was located in the
uterine body, focally occupying the cervix (Fig. 1).
Microscopically, the tumor cells were arranged in loose,
solid, or solid-tubular nests in a focal papillary manner.
Most of the tumor cells possessed abundant oncocytic cyto-
plasm and enlarged round or oval nuclei with prominent
nucleoli (Fig. 2). The tumor invaded more than half of the
myometrium. Intraepithelial extension to the cervical
glands was focally observed (Fig. 3). Oncocytic metaplasia
was not found in the non-neoplastic endometrial glands.
There was no lymph nodal metastasis.
Immunohistochemistry results revealed that the tumor
cells were positive for AMA, p53, and TTF-1 and negative
for thyroglobulin, ER, PgR, and GCDFP-15 (Fig. 4).
Immunostainings were performed on the previous breast
cancer to conWrm whether the tumor was a primarily endo-
metrial oncocytic carcinoma or whether it had metastasized
from the breast cancer. Results of immunostainings are
summarized in Tables 2 and 3.
Fig. 3 Intraepithelial extension to the endocervical glands. Hematox-
ylin and eosin, original magniWcation £40
Fig. 4 Immunohistochemistry 
of the endometrial oncocytic 
carcinoma. a Hematoxylin and 
eosin, original magniWcation 
£40. b Immunostaining for an-
timitochondrial antibody show-
ing granular positive reaction in 
tumor cytoplasm. c Expression 
of TTF-1 was occasionally 
observed in tumor nuclei. 
d Expression of p53 was 
frequent in tumor nuclei
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nests with stromal invasion, and possessed eosinophilic
cytoplasm and enlarged nuclei with prominent nucleoli
(Fig. 5). Immunohistochemistry revealed that the tumor
cells were negative for AMA, TTF-1, TG, MMG, ER, PgR,
and GCDFP-15.
When the tumor cells of the endometrial cancer and
breast cancer were compared, both were found to possess
oxiphilic cytoplasm; however, they had diVerent immuno-
staining patterns.
The endometrial tumor was diagnosed as primary endo-
metrial oncocytic carcinoma because of the presence of
intraepithelial extension to the endocervical glands and
immunohistochemical proWles diVerent from those of the
breast cancer.
Discussion
Oncocytic tumors are generally known to contain oxiphilic
cytoplasm, and these tumors occur in various organs such
as the thyroid, salivary, and adrenal glands, kidney, and
breast. However, pure oncocytic carcinoma of the endome-
trium is very rare [1].
In the clinicopathologic features of oncocytic endome-
trial carcinoma about the present and reviewed cases,
mean of patient age is 67.6 years and the tumor is mainly
composed of oncocytic cancer cells, which are arranged
in glandular, solid nests in a papillary manner (Table 4)
[1].
In general, oncocytic cytoplasm contains many mito-
chondria or eosinophilic granules [1, 6–9]. Tumor cells in
endometrial oncocytic carcinoma contain many mitochon-
dria in the cytoplasm [1]. Commonly occurring breast
tumors possess eosinophilic cytoplasm, which contains
apocrine or other secretory granules. However, oncocytic
breast cancer with numerous cytoplasmic mitochondria has
also been reported [10].
In immunohistochemical analyses, oncocytic carcino-
mas are frequently positive for p53, and rarely positive for
ER and PgR [1]. Therefore, these tumors are classiWed as
type 2 endometrial cancers (Table 5).
In the present case, endometrial tumor cells were posi-
tive for antimitochondrial antibody and negative for mam-
maglobin and GCDFP-15. On the other hand, the breast
tumor was negative for antimitochondrial antibody. These
results indicate that the breast tumor did not contain many
mitochondria.
The present tumor was also positive for TTF-1. TTF-1 is
generally expressed in non-neoplastic and neoplastic thy-
roid and lung tissues. However, TTF-1-positive tumors are
rarely reported in other sites. TTF-1 expression is detected
in approximately 20% of cases of endometrioid adenocarci-
noma [3]. However, the relation between TTF-1 and the
endometrial glands is unknown. Breast cancers are gener-
ally negative for TTF-1 [11, 12].
Tamoxifen was used for postoperative chemotherapy in
this patient for 1 year. Long-term treatment with tamoxifen
frequently induces endometrial cancer. In this case, adju-













Fig. 5 Pathological Wndings of previously operated breast carcinoma.
a Low-power view showing areas of large solid nest and adjacent inva-
sive small nests. Hematoxylin and eosin, original magniWcation £20.
b Tumor cells had granular oxiphilic cytoplasm. Hematoxylin and
eosin, original magniWcation £100123
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time. Therefore, the risk of endometrial cancer caused by
this treatment is low [13].
Breast tumors frequently metastasize to the endome-
trium [4]. Therefore, endometrial oncocytic carcinoma
must be distinguished from metastasis of breast cancers.
In general, expression of mammaglobin and GCDFP-15 is
important in distinguishing breast cancer from endome-
trial cancers. However, some breast cancers, such as the
present case, are negative for these markers. Immunohis-
tochemistry for antimitochondrial antibody and TTF-1 is
useful to distinguish between endometrial oncocytic car-
cinoma and endometrial carcinoma metastasized from
breast cancer.
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